What Accelerate Diagnostics does

Accelerate Diagnostics, Inc. is a Delaware-incorporated, NASDAQ-listed (ticker AXDX) in vitro diagnostics company headquartered in Tucson, Arizona, that developed rapid antimicrobial susceptibility testing (AST) and bacterial identification solutions for hospital clinical microbiology laboratories. Its core technology is the Accelerate Pheno system, which uses proprietary optical imaging to identify bacteria and determine antibiotic susceptibility in approximately 15 minutes—compared to traditional culture-based methods that typically take one to three days. The company monetized the platform through a razor-and-blade model: selling diagnostic instruments to hospital laboratories while generating ongoing revenue from proprietary consumables and reagents used for sepsis diagnosis and antibiotic-resistance workups.

The company targeted a single end market—hospital microbiology laboratories and infectious disease departments—via a direct enterprise field-sales motion, supplemented by presence at industry conferences and medical journals. Its funding history includes a US$578,000 CARB-X grant in June 2021 to extend its rapid optical imaging approach for sepsis diagnostics, a $4 million SEC exempt offering in March 2022, and a $15 million combined public offering and private placement in January 2024. Across its history the company raised additional disclosed rounds including a $109M public offering in December 2015 and earlier venture-stage financings.

In August 2025, Accelerate Diagnostics filed for Chapter 11 bankruptcy and completed the sale of certain assets and liabilities to Indaba Capital Management, with a liquidation plan expected to take effect that will cancel all outstanding shares and warrants. Operating status is recorded as closed.

Name

Accelerate Diagnostics

Legal name

Accelerate Diagnostics, Inc.

Website

https://acceleratediagnostics.com

Company type

Public

Founded year

2012

Operating status

Closed

Headcount range

101–250 employees

Short description

Accelerate Diagnostics is an in vitro diagnostics company that developed rapid antimicrobial susceptibility testing and bacterial identification systems, including the Accelerate Pheno platform, for hospital microbiology laboratories combating sepsis and antibiotic-resistant infections. The company filed Chapter 11 bankruptcy in 2025.

Ownership category

akta.pro rank

Product category

Clinical Microbiology Diagnostics Instruments

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

akta.pro secondary industries

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks (HLAJAIAF)

Keywords

• Clinical microbiology diagnostics
• Antimicrobial susceptibility testing
• Sepsis rapid diagnostics
• Hospital infection diagnostics
• Bacterial identification systems

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Diagnostic Instruments and Consumables: The company generated revenue from the sale of diagnostic instruments (Accelerate Pheno system) and related consumables/reagents used for antimicrobial susceptibility testing in hospital laboratories

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Accelerate Diagnostics develops and sells the Accelerate Pheno diagnostic instrument and associated consumables/reagents used by hospital clinical microbiology laboratories to perform rapid bacterial identification and antimicrobial susceptibility testing. The system targets drug-resistant organisms and hospital-acquired infections, particularly sepsis, delivering identification and AST results within approximately 15 minutes to guide targeted antibiotic therapy.

Product overview

Accelerate Diagnostics is a biotechnology company that developed diagnostic solutions for antibiotic resistance and sepsis. The company's primary technology focus was on rapid optical imaging diagnostics that could identify bacteria within 15 minutes. The company underwent Chapter 11 bankruptcy proceedings in 2025, with assets sold to Indaba Capital Management as part of its liquidation plan.

Differentiator

Problem solved

Functional benefit

Products and services

• Accelerate Pheno System
• Rapid Optical Imaging Diagnostic

Quantifiable outcome

• Identification of bacteria within 15 minutes for sepsis diagnosis

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves5 records

Expansion highlights2 records

Direct peers

• bioMérieux: Global leader in clinical microbiology, offering VITEK 2 AST systems and Blood Culture ID/AST panels directly competing with Accelerate's Pheno system for hospital microbiology lab placements.
• Beckman Coulter (Danaher): Manufacturer of MicroScan AST panels and DxM microbiology platforms, a direct competitor to Accelerate Pheno in rapid bacterial ID/AST for hospital labs.
• Becton Dickinson (BD): Provides BD Phoenix M50 AST system and BD MAX molecular platforms for infectious disease diagnostics, competing head-to-head in hospital microbiology.
• Thermo Fisher Scientific: Owns the Sensititre AST product line and Microbial ID/AST reagents, directly comparable to Accelerate's consumables-driven AST workflow.
• T2 Biosystems: Developer of T2Bacteria and T2Candida direct-from-blood molecular panels for rapid sepsis diagnostics, an emerging direct competitor in rapid bloodstream infection ID.

Emerging players

• Q-linea: Swedish developer of ASTar rapid phenotypic AST system, a near-direct comparator to Accelerate Pheno in delivering hours-not-days AST results.
• Bruker Daltonics: Sells MALDI Biotyper for rapid bacterial ID from culture and IR Biotyper for AST, overlapping with Accelerate's rapid-ID value proposition.
• Specific Diagnostics: Develops rapid phenotypic AST using proprietary sensing, directly comparable technology targeting the same rapid-AST opportunity Accelerate pursued.

Broad incumbents

• Roche Diagnostics: Through acquired GenMark ePlex and broader microbiology footprint, Roche is a broad incumbent competing in syndromic infectious disease diagnostics used by the same hospital labs.
• Danaher (Cepheid): Owns Cepheid GeneXpert molecular diagnostics widely deployed in hospital labs for rapid infectious disease testing, the dominant rapid molecular incumbent.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/axdxnews
• LinkedInlinkedin.com/company/accelerate-diagnostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds12 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelerate Diagnostics